Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population
Abstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are indicated for patients with all phenotypes of heart failure (HF). Despite the current unprecedented super-aged society in real-world settings, the efficacy of SGLT2 inhibitors in super-aged HF patients, especially those of ≥80 years, remains unknown.
METHOS: This study was conducted across three hospitals in Japan, including 238 HF patients ≥80 years (mean 84.2 ± 3.3 years), who were treated with SGLT2 inhibitors (dapagliflozin or empagliflozin). SGLT2 inhibitors were used for HF, with preserved ejection fraction in 131 patients (55.0 %), mildly-reduced ejection fraction in 54 patients (22.7 %), and reduced ejection fraction in 53 patients (22.3 %). Among 238 patients, 191 (80.3 %) continued SGLT2 inhibitors, while 47 (19.7 %) discontinued SGLT2 inhibitors (for any reason) during follow-up. The primary outcome was a composite of cardiovascular death or worsening HF, with a median follow-up duration of 2.73 (2.08-3.52) years.
RESULTS: Cumulative incidence curves modified by the Simon-Makuch method with a time-varying Cox regression analysis showed that HF patients with continued SGLT2 inhibitor treatment had significantly favorable outcomes, which remained consistent after adjustment for baseline characteristics by propensity score matching, and discontinuation of SGLT2 inhibitors was the strongest contributing factor to the outcome by a multivariable analysis. Moreover, the multivariable analysis identified a…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 238 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.